AMP 2013 Corporate Workshop Day – Host Companies

Abbott Molecular, Inc.*
Adaptive Biotechnologies Corp.
Affymetrix, Inc.
Agilent Technologies*
Asuragen, Inc.*
ATCC
AutoGenomics, Inc.
Baylor College of Medicine - Cancer Genetics Laboratory
BioFire Diagnostics, Inc.*
Biofortuna Ltd
Bio-Rad Laboratories
Cepheid
Cleveland Clinic Laboratories
ELITechGroup Molecular Diagnostics
Focus Diagnostics
GenMark Diagnostics
Genoptix Medical Laboratory
Hologic*
HTG Molecular
Illumina, Inc.*
IncellDx, Inc.
Ingenuity Systems
InVitae
Invivoscribe Technologies, Inc.
Life Technologies*
Lucigen
Luminex Corporation
Maverix Biomics, Inc.
Meridian Bioscience, Inc.
Nanosphere*
NanoString Technologies*
PerkinElmer, Inc.
Personalis
Porex Corporation
PrimeraDx
Promega Corporation
QIAGEN, Inc.*
Quidel Corporation
Roche Applied Science*
Roche Molecular*
Sequenom, Inc.
SeraCare Life Sciences
STEMCELL Technologies, Inc.
Sunquest Information Systems, Inc.

*AMP Corporate Partner Company
<table>
<thead>
<tr>
<th>START</th>
<th>END</th>
<th>TITLE</th>
<th>HOST</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>Clinical Laboratory Standards for NextGen Sequencing</td>
<td>SeraCare Life Sciences</td>
<td>Paradise Valley</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>Design for Manufacture of a Microfluidic Diagnostic for Cardiac Health</td>
<td>Porex Corporation</td>
<td>Camelback A</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>Implementation and Clinical Utility of Genomic Applications</td>
<td>Illumina, Inc.</td>
<td>Camelback B</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>Maxwell® Personalized Workflow Flexibility for Nucleic Acid Extraction</td>
<td>Promega Corporation</td>
<td>North Mountain</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td><em>Mycoplasma Pneumoniae</em>: Understanding the Importance of Rapid Diagnosis and Appropriate Treatment</td>
<td>Meridian Bioscience, Inc.</td>
<td>Valley of the Sun Ballroom A</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>New FDA Cleared FilmArray® Blood Culture Identification Panel</td>
<td>BioFire Diagnostics, Inc.</td>
<td>Valley of the Sun Ballroom E</td>
</tr>
<tr>
<td>8:00 AM</td>
<td>8:50 AM</td>
<td>Advances in Ion Torrent™ Next-generation Sequencing</td>
<td>Life Technologies</td>
<td>Encanto A</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>Characterizing Cancer Driver Gene Mutations in Solid Tumors</td>
<td>Sequenom, Inc.</td>
<td>Phoenix Ballroom E</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>Improving Test Utilization in Molecular Diagnostics – A Team Approach</td>
<td>Cleveland Clinic Laboratories</td>
<td>Valley of the Sun Ballroom D</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>Maxwell® Compatibility with Demanding Downstream Techniques</td>
<td>Promega Corporation</td>
<td>North Mountain</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>Measuring MRD in Lymphoid Malignancies and Profiling TILs in Solid Tumors using Next-Generation Sequencing</td>
<td>Adaptive Biotechnologies Corp.</td>
<td>Encanto B</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>New OncoScan™ FFPE Assay Kit: From Solid Tumor FFPE Tissue to Whole-Genome Profiling in 48 Hours</td>
<td>Affymetrix, Inc.</td>
<td>Phoenix Ballroom A</td>
</tr>
<tr>
<td>9:00 AM</td>
<td>9:50 AM</td>
<td>Rapid, Single-tube Detection of RNA and DNA Targets Using Isothermal Loop-mediated Amplification (LAMP)</td>
<td>Lucigen</td>
<td>Valley of the Sun Ballroom B</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>Analytical and Clinical Validation Results of the FDA-approved Therascreen EGFR Test</td>
<td>QIAGEN, Inc.</td>
<td>Deer Valley</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>Droplet Digital PCR: Emerging Applications in Molecular Pathology</td>
<td>Bio-Rad Laboratories</td>
<td>Paradise Valley</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>Infectious Disease Testing and Validation &amp; QC Tools</td>
<td>Life Technologies</td>
<td>Encanto A</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>Quidel's Simplified Extraction-Free Assays: Reduce Complexity and Provide Accurate Results</td>
<td>Quidel Corporation</td>
<td>Camelback B</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>Simplifying RNA-based Next Generation Aequencing (NGS) Workflows</td>
<td>Maverix Biomics, Inc.</td>
<td>Camelback A</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>10:50 AM</td>
<td>STR Analysis Technologies: Studies of Microsatellite Instability (MSI) and Mixed Human DNA Analysis with Multiplex STR Technology</td>
<td>Promega Corporation</td>
<td>North Mountain</td>
</tr>
<tr>
<td>TIME</td>
<td>HOST</td>
<td>TITLE</td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>-----------------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10:00 AM</td>
<td>Affymetrix, Inc.</td>
<td>Toward Precision Medicine: Genetic Biomarker Signature Discovery and Development for the Clinic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Invitae</td>
<td>Reinventing Genetic Testing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>AutoGenomics, Inc.</td>
<td>A Novel Prognostic and Diagnostic Tool for Management of Static Neuro-mopathy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Abbott Molecular, Inc.</td>
<td>Biomarker Testing in Lung Cancer: Making the Most of a Small Amount of Tissue</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>PerkinElmer, Inc.</td>
<td>Comprehensive Solutions for Molecular Pathology Laboratories: Sample Prep, aCGH and NGS</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Luminex Corporation</td>
<td>Rapid Detection of Gastrointestinal Pathogens using the Luminex XTAG® (GPP); Benefits for Patient, Physician and Laboratories</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Asuragen, Inc.</td>
<td>Clinical Applications for Next-Generation Sequencing</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Luminex Corporation</td>
<td>Where are You on the IS? Current and Future Relevance of IS Standardization</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>STEMCELL Technologies, Inc.</td>
<td>Improve your Assay Sensitivity for CLL and Multiple Myeloma with STEMCELL Technologies Powerful Cell</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Abbott Molecular, Inc.</td>
<td>Scaling Variant Interpretation of Next Generation Sequence Panels and Exomes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Ingenuity Systems</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>HTG Molecular</td>
<td>The Simple and Accurate System for RNA Analysis – The HTG Edge System</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>QIAGEN, Inc.</td>
<td>Exome Sequencing of Flow Sorted Hodgkin and Reed-Sternberg Cells in Primary Classical Hodgkin Lymphoma</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Life Technologies</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Roche Applied Science</td>
<td>New Testing Paradigms for Research in Cancer and Inherited Disease - ENDS AT 1:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Personalis North Mountain</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>HTG Molecular</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>North Mountain</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom A</td>
<td>PharMingen® QIAprepex® and QIAprep® ExoFast Automation Exomes - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom B</td>
<td>New Testing Paradigms for Research in Cancer and Inherited Disease - ENDS AT 1:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom C</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom D</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom E</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom F</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1:00 PM</td>
<td>Phoenix Ballroom G</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom H</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom I</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom J</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom K</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom L</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom M</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom N</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom O</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom P</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom Q</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom R</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom S</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom T</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom U</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom V</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom W</td>
<td>The Role of Molecular Profiling in Myeloid Malignancies</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom X</td>
<td>The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom Y</td>
<td>Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis, and CT/NG</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Phoenix Ballroom Z</td>
<td>Testing on an Integrated, Fully Automated Instrument - ENDS AT 2:50 PM</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TIME</td>
<td>SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>----------</td>
<td>---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Efficacy of Molecular Testing to Assess MRSA in Transplant and other Patient Populations</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Late Breaking News from the Clinical Exome Program</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>The Evolution of Clonality Testing - from Fragment Analysis to Next-Generation Sequencing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>The Latest Developments from NanoString Technologies for Multiplexed Clinical Assays</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>2:00 PM</td>
<td>Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Advances in Next-Gen Mdx: Emerging Diagnostic Approaches to Improve Patient Outcomes</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Laboratory Testing for Herpes Simplex Virus Central Nervous System Infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:00 PM</td>
<td>Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3:30 PM</td>
<td>Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>Targeted Molecular Diagnostics for Rapid Identification of Bloodstream Infections</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>The QIAGEN GeneReader™ Sample to Insight NGS Workflow</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4:00 PM</td>
<td>The Molecular Lab Integration with Clinical Systems: Scalable Workflows Clinical-level Quality &amp; Operational Efficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
8:00 AM – 8:50 AM

Clinical Laboratory Standards for NextGen Sequencing  
Room: Paradise Valley  
Time: 8:00 AM - 8:50 AM  
Hosted by: SeraCare Life Sciences

The rapid deployment of NextGen Sequencing in clinical labs is transforming MDx for genetic testing, oncology and infectious disease patient management. Heidi Rehm will present her work in optimizing NGS technologies and variant interpretation across targeted, exome and genome approaches for use in medical diagnostics and disease prediction. Jonathan Li will discuss the clinical implications of drug-resistant HIV minority variants, the use of NGS to identify drug resistance and the importance of validation and quality controls. Russell Garlick will detail the need for quality controls that mimic patient samples as well as the application of SeraCare AccuType™ viral isolates. Dr. Heidi Rehm – Optimizing Next Generation Sequencing for Clinical Use. Dr. Jonathan Li – Clinical Implications from HIV-1 Drug Resistance Testing. Dr. Russell Garlick – Addressing Validation Challenges with AccuType Viral Isolates

Design for Manufacture of a Microfluidic Diagnostic for Cardiac Health  
Room: Camelback A  
Time: 8:00 AM - 8:50 AM  
Hosted by: Porex Corporation

This presentation will explore the design for manufacture development phase of an award winning medical microfluidic system that is being validated by six major clinical trials for the areas of cardiac heart disease, oral cancer, prostate cancer, ovarian cancer and drug of abuse testing. The work is the result of a private-public partnership between the McDevitt laboratory, the pioneers of the Programmable Bio-Nano-Chip (pBNC) System, alongside Porex and MiniFAB Corporations. Critical steps will be highlighted in the development of the rapid, sample-to-answer pBNC technology, and about new opportunities for next generation multiplex and multiclass testing for research and clinical environments.

Implementation and Clinical Utility of Genomic Applications  
Room: Camel Back B  
Time: 8:00 AM - 8:50 AM  
Hosted by: Illumina, Inc.

The workshop will cover: The Utility of Illumina’s SNP Array Technology for Detecting Whole Genome Copy Number Variants from FFPE Samples presented by Natasa Dzidic, Ph.D., CombiMatrix. In addition, MiSeqDx Cystic Fibrosis Carrier Screening Assay: Our Clinical Study Experience will be presented by Julie Woolworth, Ph.D., Medical University of South Carolina.

Maxwell® Personalized Workflow Flexibility for Nucleic Acid Extraction  
Room: North Mountain  
Time: 8:00 AM - 8:50 AM  
Hosted by: Promega Corporation

The Maxwell® family of instruments extract nucleic acid using novel paramagnetic particles, allowing optimal capture, wash, and elution of the target material. The unique design of Maxwell® eliminates liquid handling and the associated clogs, drips, splashing and aerosols, greatly reducing any cross contamination risk. In this workshop a user will present research data generated using the Maxwell® 16 Instrument and Viral TNA kit for nucleic acid extraction, and discuss how the workflow fits in her lab. Additionally, a Promega scientist will present data on how the new IVD Maxwell® CSC system produces high quality DNA and RNA from FFPE samples suitable for use in downstream IVD assays.

Mycoplasma Pneumoniae: Understanding the Importance of Rapid Diagnosis and Appropriate Treatment  
Room: Valley of the Sun Ballroom A  
Time: 8:00 AM - 8:50 AM  
Hosted by: Meridian Bioscience, Inc.

Dean S. Edell, M.D., M.P.H. will discuss Mycoplasma pneumoniae along with the clinical and economic implications of the disease. Topics discussed will also include past and current test methodologies.

New FDA Cleared FilmArray® Blood Culture Identification Panel  
Room: Valley of the Sun Ballroom E  
Time: 8:00 AM - 8:50 AM  
Hosted by: BioFire Diagnostics, Inc.

The FilmArray Blood Culture Identification (BCID) Panel received FDA-clearance in June, 2013. With one test, you can identify pathogens in 9 out of 10 positive blood cultures in about an hour with only two minutes of hands-on time. The panel detects 27 targets, including Gram Negative Bacteria, Gram Positive Bacteria, Yeast and Antibiotic Resistance Genes. This workshop will provide a summary of the clinical studies performed and highlights the experience of a clinical trial site. For additional information, please visit BioFire Diagnostics’ booth (#323) or www.filmarray.com.
9:00 AM – 9:50 AM

Advances in Ion Torrent™ Next-generation Sequencing

Room: Encanto A  Time: 9:00 AM - 9:50 AM  Hosted by: Life Technologies

Now, more research laboratories can adopt powerful next-generation sequencing technology to get answers faster - with increased throughput, higher accuracy, and the simplest workflow from sample preparation through to data analysis. With the Ion Torrent™ Personal Genome Machine® (PGM) System, clinical researchers can perform a variety of targeted gene sequencing applications, such as variant detection in cancer and genetic disorders. This session will focus on the latest developments at Ion Torrent that will help make affordable next-generation sequencing accessible to clinical research laboratories around the world. For Research Use Only. Not for use in diagnostic procedures.

Characterizing Cancer Driver Gene Mutations in Solid Tumors

Room: Phoenix Ballroom E  Time: 9:00 AM - 9:50 AM  Hosted by: Sequenom, Inc.

The development of Next Generation Sequencing (NGS) enables comprehensive screening of somatic mutations across 10s to 100s of genes. However, its application may be impractical when only driver mutations or definitive biomarker profiles are being investigated due to the large data sets generated. Therefore a targeted approach seems more appropriate when screening for actionable somatic mutations. The workshop will describe use of MALDI-TOF mass spectrometry (MassARRAY® System) as a flexible, high-throughput solution that can easily adapt to newly discovered mutations as well as the detection of minority alleles of mutated DNA in large sample sets.

Improving Test Utilization in Molecular Diagnostics – A Team Approach

Room: Valley of the Sun Ballroom D  Time: 9:00 AM - 9:50 AM  Hosted by: Cleveland Clinic Laboratories

The workshop will share the test utilization strategies that have been employed at the Cleveland Clinic with an emphasis on molecular diagnostics. We will discuss the collaborative, team approach to building a functional test utilization committee. The importance and benefits of partnering with the information technology leadership and the restriction of genetic tests to particular users will be covered. We will illustrate the challenges in genetics and genomic test review and how it develops and strengthens collaboration among laboratory-based genetic counselor, molecular genetic pathologists, clinical geneticists, and ordering clinicians.

Maxwell® Compatibility with Demanding Downstream Techniques

Room: North Mountain  Time: 9:00 AM - 9:50 AM  Hosted by: Promega Corporation

The Maxwell® 16 automated systems provide consistent, reliable DNA and RNA from a variety of sample types, including Blood, FFPE and Viral Total Nucleic Acid Purification. Emergence of new downstream analysis techniques like Next Generation Sequencing and Digital PCR has placed additional demands on the purification operation. In this workshop, laboratories will share their research experience using the new Maxwell® DNA FFPE and simplyRNA Purification Kits to purify nucleic acid for use in challenging downstream assays. Results presented will include yield and nucleic acid quality data, comparison to other methods, and performance in Next Generation Sequencing as well as qPCR.

Measuring MRD in Lymphoid Malignancies and Profiling TILs in Solid Tumors using Next-Generation Sequencing

Room: Encanto B  Time: 9:00 AM - 9:50 AM  Hosted by: Adaptive Biotechnologies Corp.

Adaptive Biotechnologies' commercial products combine the capabilities of a proprietary multiplex PCR methodology with ultra high-throughput sequencing to profile T cell and B cell receptor repertoires. This unprecedented capability is complemented by powerful analytical software tools that facilitate analysis, visualization, comparison and reporting of TCR or BCR sequence data. Adaptive’s CLIA certified assay, clonoSEQ (clonoSEQ.com), is designed to monitor minimal residual disease (MRD) in hematologic malignancies with greater accuracy and sensitivity than flow cytometry. Additionally, Adaptive’s platform, quanTILfy, is designed to quantify and determine the clonality and diversity of tumor infiltrating lymphocytes (TILs) to assess prognosis of disease.

New OncoScan™ FFPE Assay Kit: From Solid Tumor FFPE Tissue to Whole-Genome Profiling in 48 Hours

Room: Phoenix Ballroom A  Time: 9:00 AM - 9:50 AM  Hosted by: Affymetrix, Inc.

Dr. Joshua Schiffman and Dr. Lulu Wang will address the utility of data recently generated using OncoScan™ FFPE Assay Kit to detect clinically relevant chromosomal aberrations. They will describe insights gleaned from the OncoScan kit, which detects genome-wide copy number changes, LOH, and key somatic mutations – all in one assay requiring only 80 ng of degraded FFPE-derived DNA. Discussion will include advantages of using this approach relative to other techniques such as FISH, PCR, aCGH, and NGS, as well as advances in understanding cancer detection, prognosis determination, and therapeutic selection. OncoScan FFPE Assay Kit is for research use only.
Rapid, Single-tube Detection of RNA and DNA Targets Using Isothermal Loop-mediated Amplification (LAMP)

*Room:* Valley of the Sun Ballroom B  
*Time:* 9:00 AM - 9:50 AM  
*Hosted by:* Lucigen

Isothermal amplification technology can offer faster and less reagent-intensive molecular detection that requires simpler and lower cost instrumentation than PCR. Several isothermal amplification methods exist, but many rely on complex protocols, multiple enzymes or special reagents to perform RNA-dependent amplification. This workshop will highlight OmniAmp™, an isothermal amplification polymerase ideally suited for loop-mediated amplification (LAMP). OmniAmp™ uniquely amplifies either RNA or DNA targets in a single tube, single buffer system and provides faster time to result. We will highlight detection of viral hemorrhagic fevers, influenza and Clostridium difficile and describe OEM/bulk supply capabilities.

10:00 AM – 10:50 AM

Analytical and Clinical Validation Results of the FDA-approved Therascreen EGFR Test

*Room:* Deer Valley  
*Time:* 10:00 AM - 10:50 AM  
*Hosted by:* QIAGEN, Inc.

QIAGEN is the world’s leading independent provider of molecular technologies for personalized healthcare currently offering over 34 commercial assays. Solidifying its leadership position in companion diagnostics, QIAGEN recently launched the FDA-approved therascreen EGFR RGQ PCR Kit (therascreen EGFR test) in the US for in vitro diagnostic use. The therascreen EGFR test is approved as a companion diagnostic for GILOTRIF (afatinib), in NSCLC patients. This companion diagnostic detects 21 analytically validated EGFR mutations, including the most prevalent resistance mutation (T790M). Analytical and clinical validation data of the therascreen EGFR test will be presented. Speaker: Jonathan Perkins, PhD, Manager PHC, QIAGEN Manchester

Droplet Digital PCR: Emerging Applications in Molecular Pathology

*Room:* Paradise Valley  
*Time:* 10:00 AM - 10:50 AM  
*Hosted by:* Bio-Rad Laboratories

Droplet Digital PCR (ddPCR) technology provides an elegant and fast method for the absolute quantification of nucleic acids without dependence on a standard curve. With the recent launch of the QX200, Bio-Rad Laboratories now offers a ddPCR platform that is compatible with probe-based assays and intercalating dyes for use with primers. In addition, the QX200 is an effective tool for the study of a wide range of sample types that have traditionally presented challenges in real-time PCR including whole blood samples and FFPE. We will highlight the use of ddPCR for non-invasive detection and absolute quantification in the areas of cancer biomarkers, viral reservoirs, and genomic variation in copy number. Benefits of ddPCR for these applications include improved sensitivity, unparalleled precision, and simplified data analysis. Finally we will present the role of ddPCR in light of the emergence of Next Generation Sequencing (NGS) techniques. DdPCR technology complements NGS both upstream of the workflow, through accurate library quantification and downstream, through the validation of NGS data. Speaker: Foina Hanner

Infectious Disease Testing and Validation & QC Tools

*Room:* Encanto A  
*Time:* 10:00 AM - 10:50 AM  
*Hosted by:* Life Technologies

The use of molecular tests to detect infectious diseases has increased dramatically. Compared to older methods, the ability to accurately identify pathogens quickly, simply, and inexpensively is becoming a reality. Validation and quality control of molecular testing is essential to ensure reliable assay results. Attend our workshop and gain insight into how Life Technologies solutions can help shape the future of your laboratory research. For Research Use Only. Not for use in diagnostic procedures.

Quidel's Simplified Extraction-Free Assays: Reduce Complexity and Provide Accurate Results

*Room:* Camelback B  
*Time:* 10:00 AM - 10:50 AM  
*Hosted by:* Quidel Corporation

Quidel is committed to providing simplified molecular diagnostic solutions for on demand testing while also providing the flexibility to test in batches for higher throughput needs. Traditional RT-PCR assays require complex sample preparation and nucleic acid extraction that typically require technical expertise and hands-on time to perform. Advances in molecular testing for infectious disease have eliminated the need for these procedures for certain assays, while providing clinically relevant and accurate results. In this workshop you will hear our speakers review clinical data and study results utilizing Quidel’s extraction-free sample preparation using AmpliVue® HDA assays and Quidel Molecular RT-PCR assays.

Simplifying RNA-based Next Generation Sequencing (NGS) Workflows

*Room:* Camelback A  
*Time:* 10:00 AM - 10:50 AM  
*Hosted by:* Maverix Biomics, Inc.

The adoption of NGS is being hampered by workflow challenges that are becoming more pronounced in clinical settings. In this session we will show how the Maverix Analytic Platform for RNA-seq has been used to simplify and streamline NGS workflows downstream of next generation sequencing instruments, reducing the hurdles encountered in the clinical implementation of NGS.
STR Analysis Technologies: Studies of Microsatellite Instability (MSI) and Mixed Human DNA Analysis with Multiplex STR Technology
Room: North Mountain Time: 10:00 AM - 10:50 AM Hosted by: Promerica Corporation

Featuring accomplished speakers discussing how they apply Promerica STR technologies in the clinical research field. Dr. Richard Halberg of the University of Wisconsin Department of Medicine will present new sensitive methods of MSI analysis for different tissue types. Dr. Donald Kristt, Rabin Medical Center, Israel, will present results of his comparative study of mixed sample analysis using Promerica’s PowerPlex 16HS STR kit and a powerful data analysis software from SoftGenetics.

Toward Precision Medicine: Genetic Biomarker Signature Discovery and Development for the Clinic
Room: Phoenix Ballroom A Time: 10:00 AM - 10:50 AM Hosted by: Affymetrix, Inc.

RNA in formalin-fixed paraffin-embedded (FFPE) samples can be difficult to measure and quantitate due to degradation of the RNA and chemical modifications caused by formalin. These lectures will discuss how useful information can be obtained by GeneChip® microarray profiling of archival FFPE tumor samples to discover unique, disease-specific gene expression signature panels. Dr. W. Fraser Symmans from MD Anderson Cancer Center and Dr. John S. Hall from the University of Manchester will describe how gene expression profiling and subsequent validation by QuantiGene® Plex Assay may be used to create diagnostic and prognostic tools for more effective cancer management.

11:00 AM – 11:50 AM

Reinventing Genetic Testing
Room: Valley of the Sun Ballroom E Time: 11:00 AM - 11:50 AM Hosted by: Invitae

Specializing in genetic diagnostics for hereditary disorders, Invitae’s mission is to make multi-gene testing more accessible and affordable than ever before. Join us to hear Federico A. Monzon, MD, Molecular Pathologist, Invitae and Jim M. Ford, MD, Associate Professor of Medicine and Genetics, Director of Stanford Program for Clinical Cancer Genomics, Stanford University School of Medicine, discuss the initial validation and the clinical impact of a multi-gene panel for hereditary cancer risk assessment. Learn how Invitae is reinventing genetic testing.

A Novel Prognostic and Diagnostic Tool for Management of Statin Neuro-myopathy
Room: Valley of the Sun Ballroom D Time: 11:00 AM - 11:50 AM Hosted by: AutoGenomics, Inc.

Statins are the most prescribed drugs in the world, used to manage elevated concentrations of low-density lipoprotein cholesterol (LDLc). There are more than 40 million Americans with high cholesterol of which 20 million are currently prescribed the statin class of cholesterol lowering drugs. Statin induced neuro-myopathy (SINM) is the main clinical management challenge of these drugs, particularly when treatment targets are aggressive. The severity of SINM does vary and in extreme cases will result in termination of treatment due to toxicity. A novel test system is proposed which will provide prognostic and diagnostic benefits when managing statin patients.

Biomarker Testing in Lung Cancer: Making the Most of a Small Amount of Tissue
Room: Encanto B Time: 11:00 AM - 11:50 AM Hosted by: Abbott Molecular, Inc.

Recent and continued discoveries are revealing significant biomarkers and associated targeted therapies in Non-small Cell Lung Cancer. The panelists will cover the most current biomarkers being considered in evaluation of lung tumors, as well as the most recent approaches and terminology being used to classify them. In addition, they will review and investigate options for optimizing and maximizing testing ability on challenging, small tissue samples. Speakers: Dr. Weiqiang Zhao, Director, Clinical & Research, Department of Pathology, Wexner Medical Center at The Ohio State University; Dr. Harry Hwang, Director of Molecular PathologyPhenoPath Laboratories; and Dr. Steven Moore, Associate Director of Cytogenetics and Molecular DiagnosticsKnight Diagnostics Institute.

Comprehensive Solutions for Molecular Pathology Laboratories: Sample Prep, aCGH and NGS
Room: Phoenix Ballroom D Time: 11:00 AM - 11:50 AM Hosted by: PerkinElmer, Inc.

With rapid advances in prenatal, neonatal and oncology testing, clinicians are challenged to stay current on what tests to order, how to interpret results and what to tell their patients. PerkinElmer offers a suite of tools and extensive laboratory network that specializes in those needs while enabling earlier, more accurate results for the greatest possible insight. PerkinElmer offers a wide range of testing service laboratories that encompass traditional cytogenetic testing including karyotyping, FISH and Fragile X screening; more advanced microarray assays specifically designed to address the variable needs of prenatal, postnatal and oncology laboratories, physicians and their patients and next generation sequencing services. Moreover, PerkinElmer can help facilitate internalization of such testing methodologies with a comprehensive suite of informatics, in vitro imaging and sequencing sample preparation solutions, as well as many kits and reagents necessary for nucleic acid extraction and analysis. In this session we will present the latest technologies, services, equipment and reagents available to support comprehensive solutions for the evolving molecular pathology laboratory.
Rapid Detection of Gastrointestinal Pathogens using the Luminex xTAG® (GPP): Benefits for Patient, Physician and Laboratorian

**Room:** Phoenix Ballroom B  
**Time:** 11:00 AM - 11:50 AM  
**Hosted by:** Luminex Corporation

This presentation will discuss a public health laboratory’s perspective for evaluation, validation and integration of the Luminex GPP as a routine test. The goal is to describe benefits of early adoption, optimization, integration challenges and reporting. In addition, be one of the first to hear about the most evolved Sample-to-Answer systems. With integrated sample preparation, analysis and detection, it is designed to fit seamlessly into any clinical lab environment.

Mike McDermott is a Microbiologist / Molecular Biologist and Molecular Biology Section Leader at the Oklahoma State Dept of Health Public Health Laboratory. Mike has worked in most sections of the Public Health Laboratory during his 18 years of employment. He is responsible for development, implementation and validation of new molecular assays. He performs and oversees a variety of molecular testing including the Luminex GPP, CFTR screening, Salmonella Serotyping Assay, Pulse-Field Gel Electrophoresis as well as various real-time PCR assays. He is an active participant in CDC’s PulseNet, ASM and APHL. He is also responsible for hospital outreach and training as the ELC Hospital Liaison for Oklahoma. Mike is also a Microbiology professor at Rose State College in Oklahoma City. Speaker: Mike McDermott, Molecular Biology Section Leader, ELC Laboratory Liaison, Oklahoma State Department of Health Public Health Laboratory.

Where are You on the IS? Current and Future Relevance of IS Standardization

**Room:** Phoenix Ballroom (E)  
**Time:** 11:00 AM - 11:50 AM  
**Hosted by:** Asuragen, Inc.

This workshop will cover standardization of BCR-ABL1 quantitative RT-PCR testing on the International Scale (IS). Experts in the field will present on the background, rationale, current efforts, progress and future directions of IS standardization. Topics discussed will include the benefits of proficiency testing and independent quality assessment programs and the performance of US laboratories that have converted their BCR-ABL1 testing to the IS. Also addressed will be the updated NCCN recommendations and the clinical importance of CML monitoring on the IS for patients on TKI therapy, including for 2nd generation TKIs and long-term monitoring of molecular response after therapy cessation.

12:00 PM – 12:50 PM

Clinical Applications for Next-Generation Sequencing

**Room:** Deer Valley  
**Time:** 12:00 PM - 12:50 PM  
**Hosted by:** Illumina, Inc.

The topic of Experience Evaluating, Validating and Implementing Next Generation Sequencing for Solid Tumors will be addressed by Dr. Dara Aisner, Ph.D., University of Colorado. In addition, Ten Month Experience with Routine NGS Testing of Hematologic and Solid Tumors: What’s Next? will be presented by Robert Daber, Ph.D., University of Pennsylvania.

Improve your Assay Sensitivity for CLL and Multiple Myeloma with STEMCELL Technologies’ Powerful Cell Isolation Platforms

**Room:** Camelback B  
**Time:** 12:00 PM - 12:50 PM  
**Hosted by:** STEMCELL Technologies, Inc.

Cell isolation can greatly enhance the sensitivity of downstream molecular assays. This workshop will highlight data showing that B cell enrichment using RosetteSep™ can improve the sensitivity of molecular assays for CLL by reducing the effects of normal clone contamination. We will also discuss data demonstrating that plasma cell enrichment allows much higher genetic abnormality detection rates by FISH, and that RoboSep™, the fully automated cell separator, offers superior performance in CD138+ cell isolation compared to a column-based platform.

m2000 System: Using One Solution to Expand Your Molecular Laboratory

**Room:** Encanto B  
**Time:** 12:00 PM - 12:50 PM  
**Hosted by:** Abbott Molecular, Inc.

Abbott RealTime m2000 is a trusted solution that continues to deliver quality, efficiency and menu expansion. Dr. Frederick Nolte, Director of Clinical Laboratories at Medical University of South Carolina, will share his laboratory experience with workflow optimization, savings and growth through consolidation of infectious disease and oncology testing onto a single platform. Dr. Maurice Exner, VP of R&D for Intelligent Medical Devices, Inc., will review and discuss the development process and clinical data associated with the recently launched Influenza A/B and RSV assay on the Abbott m2000 System. Speakers: Frederick S. Nolte, Ph.D., D(ABMM), F(AAM), Professor, Pathology and Laboratory Medicine, Director of Clinical Laboratories, Medical University of South Carolina, and Maurice Exner, Ph.D., D(ABMM), Vice President, Research & Development IntelligentMDx
Predicting Drug Response with Pharmacogenetic Testing: Understanding the Why and How
Room: Phoenix Ballroom B Time: 12:00 PM - 12:50 PM Hosted by: Luminex Corporation
The discovery of genetic factors, such as the cytochrome P450 (CYP) drug metabolizing genes, has added to our understanding of the clinically relevant genetic variations that may help predict drug response. We will discuss the utility of pharmacogenetic testing as an aid in determining therapeutic strategy, as well as describing new assays using multiplex xTAG® Technology, for accurate, reproducible genotyping of 2D6 and 2C19 mutations. In addition, be one of the first to hear about the most evolved Sample-to-Answer systems. With integrated sample preparation, analysis and detection, it is designed to fit seamlessly into any clinical lab environment. Dr. Sarah Jacobs-Helber is currently the Laboratory Director at Genetworx. She holds a PhD from Virginia Commonwealth University and conducted post-doctoral research at the National Institutes of Health. She has been in the clinical genetic testing area since 2006. She is currently a Director and member of the American Association of Bioanalysts and is certified in molecular genetic testing by the State of New York. Speaker: Dr. Sarah Jacobs-Helber, Genetworx, Laboratory Director

Scaling Variant Interpretation of Next Generation Sequence Panels and Exomes
Room: Camel Back A Time: 12:00 PM - 12:50 PM Hosted by: Ingenuity Systems
Next-generation sequencing is being adopted by molecular diagnostic laboratories to assess multiple genes for cancer and hereditary diseases rather than conventional single gene tests. The complexity associated with the large number of variants detected combined with the growing number of genes associated with diseases in clinical cases contribute to the interpretation bottleneck. Ingenuity’s curated content and analytic tools streamline and scale variant classification by incorporating phenotype information and up-to-date content into a scalable, repeatable, automated decision making workflow. In this workshop, you will learn from experts about their experience with these technologies and new solutions in development.

The Role of Molecular Profiling in Myeloid Malignancies
Room: Valley of the Sun Ballroom A Time: 12:00 PM - 12:50 PM Hosted by: Genoptix Medical Laboratory
Myelodysplastic Syndrome (MDS) encompasses an array of neoplastic disorders of the bone marrow (BM) that result in defective hematopoiesis and BM failure. Molecular profiling can strengthen risk classification in MDS by identifying additional molecular markers that can facilitate diagnosis, provide prognostic information and aid in the selection of appropriate therapies. In this workshop, we will highlight goals of identifying genetic and molecular markers for MDS and AML, review the International Prognostic Scoring System (IPSS) risk stratification of MDS, describe genetic abnormalities in MDS, and introduce the MDS Molecular Profile offered by Genoptix.

The Simple and Accurate System for RNA Analysis – The HTG Edge System
Room: Paradise Valley Time: 12:00 PM - 12:50 PM Hosted by: HTG Molecular
Until now, RNA analysis has been challenging to deploy reproducibly even for the most advanced laboratories. HTG Molecular Diagnostics introduces an expanded menu of probesets for use on the HTG Edge System (introduced at AMP in 2012). The award-winning Edge System is the only fully-automated RNA analysis platform that delivers extraction-free, multiplexed results on a multitude of biological samples (tissue, blood, serum, cells) in 24 hours. To support the individualized needs of your laboratory, HTG also offers a new online capability to develop your own customized probesets. A review of the system’s performance across several assays will be presented.

New Testing Paradigms for Research in Cancer and Inherited Disease – ENDS AT 1:50 PM
Room: Encanto A Time: 12:00 PM - 1:50 PM Hosted by: Life Technologies
Cancer and inherited disease research using conventional molecular analysis has relied on the detection of single genes. But recognizing the complexity of the genes involved in these diseases has led to a new focus on multigene analysis and gene regulation. Attend our workshop and hear users of Life Technologies sequencing and real-time PCR platforms describe how they identify variants in inherited disease and cancer research samples. Technologies featured will include: Ion Torrent semiconductor sequencing, Ion AmpliSeq™ target selection, QuantStudio™ 3D Digital PCR System and QuantStudio™ 12K Flex and Open Arrays® technology. For Research Use Only. Not for use in diagnostic procedures.

1:00 PM – 1:50 PM

Exome Sequencing of Flow Sorted Hodgkin and Reed-Sternberg Cells in Primary Classical Hodgkin Lymphoma
Room: Phoenix Ballroom A Time: 1:00 PM - 1:50 PM Hosted by: Roche Applied Science
We utilized flow cytometric cell isolation of viable Hodgkin Reed-Sternberg cells of primary classical Hodgkin lymphoma tumors from ten primary cases together with a modified ultra-low input library generation procedure to perform paired whole exome sequencing of ten primary cases of CHL. We identified recurrent mutations in genes involved in mitotic checkpoint regulation, epigenetic regulation and immune evasion. Speaker: Jonathan Reichel of Cornell University.
Maximizing the Value of JAK2 V617F Mutation Load Assessment in Myeloproliferative Neoplasms (MPNs) Management.

Room: Valley of the Sun Ballroom B  Time: 1:00 PM - 1:50 PM  Hosted by: QIAGEN, Inc.

JAK2 V617F is a major criterion in the diagnosis algorithm for myeloproliferative neoplasms (MPN). In some confirmed MPN patients, JAK2 V617F mutation load can be as low as 1-3%, potentially below the limit of detection of some methods used in routine diagnostics. Several clinical research publications, to be confirmed, support the value of JAK2 V617F mutation load as a prognostic factor, and as a tool to monitor minimal residual disease in post-transplant patients. This symposium will discuss the need for assay standardization, and results of a recent European LeukemiaNet and MPN&MPN-euroNet study evaluating overall performance, sensitivity and specificity of JAK2 V617F assays. Speaker: Dr Susanna Akiki, Section Head Hemato-oncology, Deputy Head Cancer Program at West Midlands Regional Genetics Laboratories, Birmingham Women's NHS Foundation Trust

The ACE Clinical Exome: A Clinical Grade Exome and Accurate Interpretation for Diagnosis of Genetic Syndromes

Room: North Mountain  Time: 1:00 PM - 1:50 PM  Hosted by: Personalis

In this workshop, we will discuss the highly accurate exome sequencing and interpretation strategies that underlie Personalis’ ACE Clinical Exome, a single test that integrates enhanced exome sequencing with genome-wide structural variant detection to increase diagnostic yield. Topics include our approaches to creating a clinical grade exome using ACE Technology, improving the sensitivity and specificity of structural variant calling, correcting the human reference sequence to enable better alignment and variant calling, and identifying disease causing variants through clinically-driven variant prioritization, annotation, and interpretation. We will present clinical examples of how these accuracy enhancements improve overall detection of causative variants in genetic syndromes.

Advances in Molecular Diagnostic Testing: Consolidation of HPV, Trichomonas vaginalis and CT/NG Testing on an Integrated, Fully Automated Instrument – ENDS AT 2:50 PM

Room: Valley of the Sun Ballroom D  Time: 1:00 PM - 2:50 PM  Hosted by: Hologic

How can you do more with less? Laboratories of all sizes face common challenges of having to produce more with less. Labs are being asked to increase testing volume and menu options while at the same time labor is becoming scarce, reimbursement is declining and budgets are being cut. One way to maximize productivity and efficiency is through consolidation of menu with integrated automation. HOLOGIC invites you to an exciting workshop which brings together key opinion leaders who will share data and perspectives on HPV, CT/NG, and Trich testing and how the consolidation of these assays onto a next generation molecular diagnostic instrument, the Panther System, can improve productivity and overall efficiency of your lab.

2:00 PM – 2:50 PM

Efficacy of Molecular Testing to Assess MRSA in Transplant and other Patient Populations

Room: Camelback A  Time: 2:00 PM - 2:50 PM  Hosted by: ELITechGroup Molecular Diagnostics

Phillip Ruiz, M.D., Ph.D., Medical Director, Transplant Laboratories at the University of Miami, will discuss the clinical and financial impact of determining MRSA status in transplant recipients and other high risk populations. Dr. Ruiz will discuss his findings and highlight the advantages and disadvantages of molecular vs. culture for MRSA detection. Dr. Ruiz’s laboratory, located within the Department of surgery, provides comprehensive diagnostic services with a focus on solid organ transplantation. With this shift into a vertical support model, he has created innovative pathways that have enhanced patient care and increased clinician satisfaction, while improving the laboratory's fiscal performance.

Late Breaking News from the Clinical Exome Program

Room: Phoenix Ballroom E  Time: 2:00 PM - 2:50 PM  Hosted by: Baylor College of Medicine - Cancer Genetics Laboratory

Please join us as we discuss our clinical exome program (both hereditary and cancer exome sequencing) and our next-generation sequencing cancer mutation panels. Presenters: Yaping Yang, Ph.D., ABMG Certified Clinical Molecular Geneticist, Director, Medical Genetics Laboratories, Baylor College of Medicine and Marilyn Li, M.D., Professor, Department of Molecular and Human Genetics, Director, Cancer Genetics Laboratory, Medical Genetics Laboratories, Baylor College of Medicine
Succeeding with Multiplex PCR in the Clinic

**Room:** Paradise Valley  
**Time:** 2:00 PM - 2:50 PM  
**Hosted by:** PrimeraDx

PrimeraDx will provide a brief outline of multimodal, multiplex technology, including the success of recent clinical collaborations and a review of RUO kits soon to be released. Dr. Belinda Yen-Lieberman of the Cleveland Clinic will relate her experience with the ICEPlex system from its early development, through a clinical trial for our Clostridia difficile test, to a new Lymphoma panel currently being validated for use at the Clinic. Dr. Bryce Portier of the Houston Methodist Hospital will discuss the benefits of the PrimeraDx approach as applied to a BCR/ABL panel during his fellowship at the MD Anderson Cancer Center.

The Evolution of Clonality Testing - from Fragment Analysis to Next-Generation Sequencing

**Room:** Phoenix Ballroom B  
**Time:** 2:00 PM - 2:50 PM  
**Hosted by:** Invivoscribe Technologies, Inc.

For almost twenty years, Invivoscribe® (invivoscribe.com) has been the worldwide leader in products for hemopathology, offering a full range of standardized RUO and CE-marked tests, ASR reagents, and GPR controls for the detection of gene rearrangements, translocations and mutations. In this symposium, new and exciting data for the detection and analysis of clonal gene rearrangements through our next-generation sequencing RUO products, the LymphoTrack™ IGH and TCRG Assays, will be presented. Results include data from our own research and development, as well as those from our collaborators in laboratory settings.

The Latest Developments from NanoString Technologies for Multiplexed Clinical Assays Powered by the nCounter System, Including The Prosigna™ Breast Cancer Prognostic Gene Signature Assay

**Room:** Camel Back B  
**Time:** 2:00 PM - 2:50 PM  
**Hosted by:** NanoString Technologies

The Prosigna™ Breast Cancer Prognostic Gene Signature Assay represents a new way to look at breast cancer tumor biology and enables fast and accurate genomic test results directly from your lab. The Prosigna assay is powered by the nCounter System, a highly automated and easy-to-use platform that utilizes a novel digital barcoding chemistry to deliver high precision multiplexed assays. The new nCounter Elements™ GPRs provide further flexibility for clinical laboratories by enabling gene expression, CNV and gene fusion signatures to be rapidly implemented as Laboratory Developed Tests.

The Value of Multiplex Molecular Methodologies to Positively Affect Change: Respiratory Virus Detection and HCV Genotyping with the eSensor® XT-8™

**Room:** Deer Valley  
**Time:** 2:00 PM - 2:50 PM  
**Hosted by:** GenMark Diagnostics

GenMark is committed to providing patient-focused solutions to diagnose disease and aid in therapy selection and dosing decisions. Together with clinical laboratory partners, GenMark is improving patient care with its innovative eSensor® XT-8™ molecular diagnostics system and an expanding menu of multiplex tests that deliver fast, accurate results. This informative 1-hour workshop will provide a forum to hear the latest breaking news about HCV genotyping and to discuss multiplex respiratory viral testing as an important clinical diagnostic tool, from the perspectives of two experts in the field.

Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles

**Room:** Phoenix Ballroom D  
**Time:** 2:00 PM - 2:50 PM  
**Hosted by:** Agilent Technologies

SureSelect and Haloplex: Building the Path Towards Clinical Research Sequencing presented by Maria Celeste M. Ramirez, Ph.D., Product Manager, Target Enrichment, Agilent Technologies. Optimizing Array Design to Maximize Detection of Genetic Abnormalities presented by Marilyn M. Li, M.D., Director, Cancer Genetics Laboratory and Professor, Baylor College of Medicine. Deep Clonal Profiling of Formalin-Fixed, Paraffin-Embedded Clinical Samples presented by Michael T. Barrett, Ph.D., Associate Professor TGen, Consultant Mayo Clinic Arizona. New! SureFISH Probes for Cancer Research presented by Stephanie Fulmer-Smentek, Ph.D., R&D Group Manager, Cytogenetics, Agilent Technologies

Advances in Next-Gen Mdx: Emerging Diagnostic Approaches to Improve Patient Outcomes – ENDS AT 3:50 PM

**Room:** Valley of the Sun Ballroom E  
**Time:** 2:00 PM - 3:50 PM  
**Hosted by:** Cepheid

In today’s healthcare environment, the overall cost of patient care is being re-evaluated as new diagnostic technologies emerge. The impact of timely and actionable laboratory results on hospital stay, isolation days and antibiotic stewardship must now be considered, in addition to direct assay-test costs, for determining the overall value to patient care. Next Generation molecular diagnostics (Mdx) deliver information that can have a positive impact on both quality of results and effective patient management. This workshop will provide insights into how Next-Gen Mdx can provide critical information with a single test, eliminating the need for time-consuming follow up testing to complete a diagnosis. These examples will cover Sexual Health (Xpert CT/NG), Women’s Health (Xpert HPV), and Critical Infectious Diseases (Xpert MTB/RIF).
2:30 PM – 4:50 PM

MD Workshop

Room: Phoenix Ballroom A  
Time: 2:30 PM - 4:50 PM  
Hosted by: Roche Molecular

Join us for three presentations! First, Optimizing HPV Testing in the Changing Healthcare Landscape - an exploration of HPV, its prevalence of infection and available testing methodologies currently on the market. We will present test validation and performance of our method of choice for cervical cancer screening, including a discussion of how adoption of this technology has benefited our laboratory and the clinicians and patients we serve. Presented by Dr. Sajo Beqaj Ph.D; Dr. Ronald Blum Ph.D

Second, Empowering Change in HCV: Trends, Treatments, and Diagnostics - addresses the promise of increasingly effective and better tolerated therapies will lead to better patient outcomes. However, treatment and management of patients will remain complex. We will offer a clinicians perspective on the rapidly evolving landscape of HCV related to trends, treatments, and diagnostics. Presente by Raj Vuppalanchi, MD, Associate Professor of Medicine, Division of Gastroenterology and Hepatology

Third, Companion Diagnostics, A Unique Operational Experience - a discussion of the role of companion diagnostic tests in the management of Oncology patients and what unique operational challenges and benefits they present. Presented by Speaker: John Longshore, PhD, FACMG

3:00 PM – 3:50 PM

Advances in Incell3Dx Technology: Novel Clinical Applications

Room: Valley of the Sun Ballroom A  
Time: 3:00 PM - 3:50 PM  
Hosted by: IncellDx, Inc.

IncellDx will present its novel molecular cellular multiplexing for both cervical cancer screening (3Dx technology) and breast cancer prognosis. We will describe a bioinformatics algorithm to incorporate morphologic parameters (N/C ratio, nuclear area, MCV), oncogene overexpression (E6, E7 mRNA), and cell cycle/proliferation for cervical cancer screening. In addition, we will describe our integrative approach in breast cancer diagnostics with an emphasis on current test limitations while addressing future applications.

Freeze Dried Hot Start PCR Mixes – The Evolution of Molecular Diagnostics

Room: North Mountain  
Time: 3:00 PM - 3:50 PM  
Hosted by: Biofortuna Ltd

Several key technological innovations have contributed to the evolution of molecular diagnostics. One such advancement is Hot Start (CleanAmp™) dNTPs, which provide a highly versatile alternative to existing Hot Start PCR methodologies. This reagent can be applied into any nucleic acid detection set-up, including lyophilized (freeze-dried) versions, by simple substitution for standard dNTPs. Advancements in freeze-drying techniques have given way to a whole new generation of lyophilized diagnostic products. These evolved diagnostic kits are stable at ambient temperatures for up to 16 months offer an easy-to-use one-step test format, which is flexible and highly accurate.

Laboratory Testing for Herpes Simplex Virus Central Nervous System Infections

Room: Encanto A  
Time: 3:00 PM - 3:50 PM  
Hosted by: Focus Diagnostics

This workshop will cover laboratory diagnostics for Herpes Simplex Virus type 1 and 2 with a particular focus on central nervous system infections and diagnosis in the neonate. Preliminary results from the Simplexa HSV 1/2 Direct clinical study will be presented along with a review of the 3M testing platform. Presenter: Amy L. Leber, Ph.D., D(ABMM), Director, Clinical Microbiology and Immunoserology, Department of Laboratory Medicine, Nationwide Children's Hospital

Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles

Room: Phoenix Ballroom D  
Time: 3:00 PM - 3:50 PM  
Hosted by: Agilent Technologies

SureSelect and Haloplex: Building the Path Towards Clinical Research Sequencing, presented by Maria Celeste M. Ramirez, Ph.D., Product Manager, Target Enrichment, Agilent Technologies. Optimizing Array Design to Maximize Detection of Genetic Abnormalities, presented by Marilyn M. Li, M.D., Director, Cancer Genetics Laboratory and Professor, Baylor College of Medicine. Deep Clonal Profiling of Formalin-Fixed, Paraffin-Embedded Clinical Samples, presented by Michael T. Barrett, Ph.D., Associate Professor TGen, Consultant Mayo Clinic Arizona. New! SureFISH Probes for Cancer Research, presented by Stephanie Fulmer-Smentek, Ph.D., R&D Group Manager, Cytogenetics, Agilent Technologies
Challenging Assay Design with ATCC Biological Materials

Room: Deer Valley  Time: 4:00 PM - 4:50 PM  Hosted by: ATCC

The use of controls in assay development is essential for determining the reliability and reproducibility of data obtained from molecular applications. ATCC has taken great strides to more fully characterize and describe cell lines and microbial cultures useful for assays targeting cancer mutations, infectious diseases, and microbial multidrug resistance. Additional work has also been performed to provide investigators with a broad range of materials, including preserved cell lines and microbial strains, native nucleic acids, quantitative synthetic nucleic acids, and certified reference materials. Join ATCC for Corporate Workshop Day to learn more about the controls you need for consistent results.

Implementing Focus Diagnostics’ Simplexa Molecular Tests

Room: Encanto A  Time: 4:00 PM - 4:50 PM  Hosted by: Focus Diagnostics

Testing for C. difficile - This lecture will review the C. difficile tests available to the clinical laboratory, with an emphasis on the currently available, IVD technologies for molecular testing. An emphasis will be placed on the clinical utility of molecular testing for the diagnosis of C. difficile disease. Presenter: Romney Humphries, PhD D(ABMM), Section Chief, Clinical Microbiology, UCLA. Sample-to-result testing using Simplexa Flu A/B & RSV Direct This presentation will cover Simplexa Flu A/B & RSV Direct moderate complexity testing with a discussion of implementation, workflow and ease of use during the 2012-2013 flu season. Presenter: Jane Kuypers, PhD, Senior Research Scientist, Director of Development, Molecular Diagnostics Laboratory, Department of Laboratory Medicine, University of Washington

Targeted Molecular Diagnostics for Rapid Identification of Bloodstream Infections

Room: Camel Back B  Time: 4:00 PM - 4:50 PM  Hosted by: Nanosphere

Early detection of infectious pathogens and timely delivery of appropriate treatment are critical in caring for patients with infectious diseases. Nanosphere, a company committed to enhancing medicine through targeted molecular diagnostics, invites you to join this session to learn about its proprietary technology, the Verigene® System, which addresses the most complex, costly and deadly infectious disease states. During this workshop, Verigene users will share real-world experiences in successfully implementing the Verigene Gram-Positive Blood Culture (BC-GP) Test at a network of hospitals.

The Molecular Lab Integration with Clinical Systems: Scalable Workflows Clinical-level Quality & Operational Efficiency

Room: Encanto B  Time: 4:00 PM - 4:50 PM  Hosted by: Sunquest Information Systems, Inc.

Clinical pathology laboratories are generally well-oiled machines utilizing paperless workflows and automation. Lessons learned from the clinical pathology, including application of LEAN methodology, are being now being applied to anatomic pathology to achieve similar levels of quality & efficiency. The Molecular Lab often remains manual and paper-driven without the ability to scale for the future increases in molecular test volume. Learn how Molecular workflow managements solutions integrated with the clinical pathology laboratory information system can drive efficiency and safety through the reduction of non-value-added activities and reduce errors.

The QIAGEN GeneReader™ Sample to Insight NGS workflow

Room: Valley of the Sun Ballroom B  Time: 4:00 PM - 4:50 PM  Hosted by: QIAGEN, Inc.

QIAGEN is pleased to present the GeneReader workflow for next-generation sequencing including products from sample preparation through variant identification. The GeneReader workflow includes a simple, NGS-platform-independent target enrichment strategy, with oncology focused, pre-designed or custom panels that allow targeted sequencing to meet the multiple varied needs of researchers. Integrated workflow components include controls that assess sample quality prior to NGS analysis. The workshop will introduce the QIAGEN GeneReader instrument, a transformational, continuous loading NGS benchtop sequencer that offers many features essential for customers in research. Speaker: Dirk Löfert, PhD Vice President, Head of Global Product Development, Global R&D QIAGEN, GmbH. Oncology Gene Panels: Screening for Mutations by Next-Generation Sequencing - Speaker: Helene Peyro-Saint-Paul, MD, PHC Oncology Portfolio Team Lead, QIAGEN Marseille, Chief Medical Officer, QIAGEN Marseille

Translating Discoveries into Clinical Applications: Using Multiple Technologies to Create Deep Genetic Profiles

Room: Phoenix Ballroom D  Time: 4:00 PM - 4:50 PM  Hosted by: Agilent Technologies

AMP celebrates 20 years!

Association for Molecular Pathology
AMP 2014 Annual Meeting

November 13 - 15, 2014
Corporate Workshop Day, November 12
Gaylord National Hotel & Convention Center, National Harbor, MD
(Just south of Washington, DC)

Mark your calendar!

www.amp.org/2014/